Calidi Biotherapeutics (CLDI) Announces 1:10 Reverse Share Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Calidi to Effect Reverse Stock Split
July 5, 2024 4:15 PM EDTCalidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024
SAN DIEGO--(BUSINESS WIRE)-- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Calidi or Company), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today announced that its Board of Directors has approved the reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 (the Reverse Stock Split). The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on July 15, 2024. The Companys... More
